Literature DB >> 7543449

A mutation in the alpha 3 domain of Db that abrogates CD8 binding does not affect presentation of an immunodominant H-Y peptide.

J P Dutz1, S J Teh, N Killeen, H S Teh.   

Abstract

The peptidic nature of the male (H-Y) antigen, a model minor histocompatibility antigen in H-2b mice, has recently been demonstrated. In this study we show that the H-Y peptide, which is recognized by PM-1, a Db-restricted cytotoxic T-lymphocyte (CTL) clone, is absent in male H-2d spleen cells but present in male H-2d spleen cells that also express a transgenic Db molecule under its endogenous promoter. This result indicates that both the H-Y and the Db gene products are essential and sufficient for production of the Db-restricted H-Y peptide. By comparing the ability of the PM-1 clone and bulk CTL generated in a secondary mixed lymphocyte culture to recognize H-Y peptidic material eluted from affinity-purified Db molecules and separated by reversed-phase high-performance liquid chromatography (HPLC), we provide evidence that there is an immunodominant H-Y epitope that is presented by the Db molecule. Furthermore, the presentation of this epitope is not affected by a mutation in the alpha 3 domain of Db (asp227 to lys227), which abrogates CD8 binding, since similar amounts of H-Y peptide were eluted from affinity-purified wild-type or mutant Db molecules. However, the generation of the H-Y epitope is dependent on the presence of beta 2-microglobulin, since it is absent in male H-2b mice that lack a functional beta 2-microglobulin gene. The implications of these findings on T-cell development are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543449      PMCID: PMC1384027     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  38 in total

1.  Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing.

Authors:  H J Wallny; O Rötzschke; K Falk; G Hämmerling; H G Rammensee
Journal:  Eur J Immunol       Date:  1992-03       Impact factor: 5.532

2.  Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection.

Authors:  D E Speiser; D Kyburz; U Stübi; H Hengartner; R M Zinkernagel
Journal:  J Immunol       Date:  1992-08-01       Impact factor: 5.422

3.  Few peptides dominate cytotoxic T lymphocyte responses to single and multiple minor histocompatibility antigens.

Authors:  L Yin; G Poirier; O Neth; J J Hsuan; N F Totty; H J Stauss
Journal:  Int Immunol       Date:  1993-09       Impact factor: 4.823

4.  A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein.

Authors:  K Udaka; T J Tsomides; H N Eisen
Journal:  Cell       Date:  1992-06-12       Impact factor: 41.582

5.  Highly lytic CD8+, alpha beta T-cell receptor cytotoxic T cells with major histocompatibility complex (MHC) class I antigen-directed cytotoxicity in beta 2-microglobulin, MHC class I-deficient mice.

Authors:  S Apasov; M Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

6.  Major histocompatibility complex class I-specific and -restricted killing of beta 2-microglobulin-deficient cells by CD8+ cytotoxic T lymphocytes.

Authors:  R Glas; L Franksson; C Ohlén; P Höglund; B Koller; H G Ljunggren; K Kärre
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

7.  Skin graft rejection by beta 2-microglobulin-deficient mice.

Authors:  M Zijlstra; H Auchincloss; J M Loring; C M Chase; P S Russell; R Jaenisch
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

8.  Requirement for CD8-major histocompatibility complex class I interaction in positive and negative selection of developing T cells.

Authors:  N Killeen; A Moriarty; H S Teh; D R Littman
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

9.  Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator.

Authors:  T N Schumacher; D V Kantesaria; M T Heemels; P G Ashton-Rickardt; J C Shepherd; K Fruh; Y Yang; P A Peterson; S Tonegawa; H L Ploegh
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

10.  In vivo and in vitro clonal deletion of double-positive thymocytes.

Authors:  N J Vasquez; J Kaye; S M Hedrick
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

View more
  1 in total

1.  Glu227-->Lys substitution in the acidic loop of major histocompatibility complex class I alpha 3 domain distinguishes low avidity CD8 coreceptor and avidity-enhanced CD8 accessory functions.

Authors:  L Shen; T A Potter; K P Kane
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.